The results came from the phase 2 THERMAC trial, which compared radiofrequency ablation, microwave ablation, and cryoablation with ProSense® in patients with early-stage breast cancer and were shown in 2 separate publications. The first was published in the European Journal of Surgical Oncology (EJSO) and covered cosmetic outcomes and patient satisfaction with ProSense® in early-stage breast cancer.2 The second was published in Radiology and covered the trial’s efficacy.3
The ProSense® cryoablation system achieved the highest complete ablation rate compared with alternatives, with 95% of patients with breast cancer being “very satisfied” or “satisfied” with the thermal ablation, according to a press release from the developer, IceCure Medical.1
The results came from the phase 2 THERMAC trial, which compared radiofrequency ablation, microwave ablation, and cryoablation with ProSense® in patients with early-stage breast cancer and were shown in 2 separate publications. The first was published in the European Journal of Surgical Oncology (EJSO) and covered cosmetic outcomes and patient satisfaction with ProSense® in early-stage breast cancer.2 The second was published in Radiology and covered the trial’s efficacy.3
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.